Navigation Links
PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference

BOSTON, Dec. 1 /PRNewswire-FirstCall/ -- An expert from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will lead a panel discussion on innovative approaches to drug development in Asia at the Partnerships in Clinical Trials Asia Pacific Conference, being held December 1-3, 2009 at the Intercontinental Hotel in Singapore. PAREXEL is a sponsor of the conference, which is focused on maximizing efficiency and maintaining quality of clinical trials in the Asia/Pacific region, as well as sharing successful strategies for introducing new products into this growth market.

During the panel session, "Asia's Pharma Industry - Innovative Drug Development," taking place on Wednesday, December 2 at 10:00 a.m., Edmund Leong, Director, Clinical Research Services, Asia/Pacific, PAREXEL will moderate a discussion featuring industry experts from Allergan, a multi-specialty health care company, and CK Life Sciences, which is engaged in the business of research and development, commercialization, marketing and sale of biotechnology products. The panelists will offer insights and experiences for successfully managing drug development in the Asia/Pacific region.

With 15 locations throughout the Asia/Pacific region, including Singapore, PAREXEL has had a long-term commitment to providing a high level of standardization and quality clinical development services in these geographies. PAREXEL helps clients address key challenges in conducting studies in the Asia/Pacific region and globally, including accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality.

Conference attendees will be able to gain insight into what types of relationships work well in the Asian/Pacific markets, and how biopharmaceutical industry professionals can explore collaboration opportunities in product development. Additional information about the Partnerships in Clinical Trials Asia Pacific Conference can be found at:

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has more than 9,130 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 as filed with the SEC on November 6, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Jennifer Baird, Senior Director of
 Public Relations                         Gene Carozza/Kim Baker
PAREXEL International                     PAN Communications
Tel: +781-434-4409                        Tel: +978-474-1900
Email:         Email:

SOURCE PAREXEL International Corporation

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
2. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
3. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
4. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
5. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
6. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
9. Malaria Experts Call on Federal Government to Increase Support for Research and Development
10. Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
11. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
Post Your Comments:
(Date:12/1/2015)... Ohio , Dec. 1, 2015 ... to its GeneSight® Psychotropic test giving healthcare providers an ... medication decisions for patients suffering from depression, anxiety, ... other behavioral health conditions. i ... --> With the addition of two ...
(Date:12/1/2015)... 2015 --> ... "Nucleic Acid Labeling Market by Product (Reagents & Kits, ... In Vitro Transcription, Reverse Transcription, End Labeling), by Region ... global market is expected to reach USD 1,925.7 Million ... at a CAGR of 8.65%. Browse 77 ...
(Date:12/1/2015)... , Dec. 01, 2015 ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ... "Veterinary Equipment and Disposables Market by product, ... report to their offering. --> Research ...
Breaking Medicine Technology:
(Date:12/1/2015)... TX (PRWEB) , ... December 01, 2015 , ... Dr. ... of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single ... of the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... have seen vast improvements in scientific research and discoveries, leading us to better ... hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot ... States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health ... contributors to diseases of the diabetic foot. The American Board of Multiple ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
Breaking Medicine News(10 mins):